Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose aflibercept vs standard-dose aflibercept for diabetic macular edema (PHOTON, Japan subset)
jRCT2080225235Phase 3Completed
- Sponsor
- Bayer
- Start
- Jun 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in diabetic macular edema (DME) (2 arms), sponsored by Bayer. Primary endpoint: Best corrected visual acuity (BCVA) non-inferiority. Started Jun 2020; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on jRCT2080225235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225235.